Nature Reviews Drug Discovery contents August 2013 Volume 12 Number 8 pp 561-644

Advertisement
Research Topics are a great method of enabling you and your colleagues to drive your field where you want to take it, by encouraging dialogue and collaboration between researchers.  Phenotypic screening in the 21st century This RT from Frontiers in Pharmacology aims to discuss strategies, key concepts and technologies related to systems-based approaches in drug development.  Find out more on how you can contribute to this RT or even host your own.
TABLE OF CONTENTS
August 2013 Volume 12 Number 8		Advertisement
Impact Factor 33.078 *	In this issue Comment News and Analysis Research Highlights Reviews Correspondence Also this month Article series: A guide to drug discovery  Featured article: Validating therapeutic targets through human genetics Robert M. Plenge, Edward M. Scolnick & David Altshuler	Integrating Pharmacometrics Summit - early registration closes 9th August 21 - 23 October | Munich This is a meeting for pharmaceutical executives who want to develop a strategy to fully integrate pharmacometrics across drug development. Attend to find out how you can evidence the value, achieve senior buy in & avoid late stage failures  Download the brochure for the full speaker line up and agenda.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Collaborate. Co-Develop. Commercialize.  Built to strengthen your companion diagnostic development, World CDx will ensure every step is as smooth as the next. Join the World CDx community to maximize the impact of your collaborations. Improve your clinical biomarker validation, embed genomic technologies into your development and achieve successful Rx/Dx co-development. www.world-cdx.com
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
nature.com webcasts Macmillan Science Communication presents a custom webcast on: Accelerating the discovery and development of monoclonal antibodies  Listen on demand, to this free webcast  Sponsored by:
In this issue p561 | doi:10.1038/nrd4076 Full Text
Comment: Towards a prevention model of health care Alasdair Breckenridge & Hans-Georg Eichler p563 | doi:10.1038/nrd4077 Health-care budgets are largely spent on treating the complications of chronic diseases, many of which have preventable risk factors. Here, we discuss some of the key issues in the necessary move towards a 'prevention model' of health care. Full Text | PDF
NEWS AND ANALYSIS		Top
Revolution dawning in cardiotoxicity testing Kelly Rae Chi p565 | doi:10.1038/nrd4083 Stem cell technology and computational modelling offer the promise of reducing the current burden of cardiotoxicity assessment. PDF
NEWS IN BRIEF EMA backs approval of first biosimilar monoclonal antibodies p568 | doi:10.1038/nrd4096 PDF
FDA approvals for first half of 2013 p568 | doi:10.1038/nrd4097 PDF
End of the line for PPAR modulators? p568 | doi:10.1038/nrd4098 PDF
BIOBUSINESS BRIEFS Trial Watch: Phase II and Phase III attrition rates 2011-2012 John Arrowsmith & Philip Miller p569 | doi:10.1038/nrd4090 PDF
PATENT WATCH Isolated DNA patent ban creates muddy waters for biomarkers and natural products Charlotte Harrison p570 | doi:10.1038/nrd4084 PDF
AN AUDIENCE WITH Lee M. Ellis p572 | doi:10.1038/nrd4085 The lead author of the ASCO's draft guidelines to "raise the bar" for cancer clinical trials discusses the aims and potential impact of the guidelines on anticancer drug development. PDF
FROM THE ANALYST'S COUCH Novelty in the target landscape of the pharmaceutical industry Pankaj Agarwal, Philippe Sanseau & Lon R. Cardon p575 | doi:10.1038/nrd4089 Agarwal and colleagues present an analysis of the overlap in the drug targets that are being pursued across the industry, which indicates that more than half of the novel drug targets in current pipelines are being pursued by only one company. PDF
RESEARCH HIGHLIGHTS Top Metabolic disease: Potassium channel blocker prevents obesity p577 | doi:10.1038/nrd4081 PDF Mood disorders: Room for improvement p578 | doi:10.1038/nrd4078 PDF Antibacterial drugs: Hitting the tuberculosis wall p578 | doi:10.1038/nrd4080 PDF G protein-coupled receptors: Two landmark class B GPCR structures unveiled p579 | doi:10.1038/nrd4082 PDF Influenza: Viral vector delivers protective antibodies p580 | doi:10.1038/nrd4079 PDF IN BRIEF Anticancer drugs: Targeting receptor-regulator interactions | Cancer: A new way to restore tumour suppressor function | Target profiling: Chaperones as thermodynamic sensors | Dermal disorders: Boosting hair follicle regeneration PDF Drug Discovery JOBS of the week Postdoctoral Research Associate - Drug Metabolism University of Washington PhD student and Postdoctoral Research Scientist Positions in Drug Discovery Shanghai Jiaotong University Senior Research Associate in Pharmacogenomics Laval University and CHU de Québec Research Center Junior Research Group Leader (M / F) German Cancer Research Center (DKFZ) Senior and Intermediate Fellowship in Biomedical Research The Wellcome Trust/DBT India Alliance More Science jobs from Drug Discovery EVENT 14th International Conference on Alzheimer's Drug Discovery 10.09.13 Jersey City, USA More science events from
REVIEWS		Top
Article series: A guide to drug discovery Validating therapeutic targets through human genetics Robert M. Plenge, Edward M. Scolnick & David Altshuler p581 | doi:10.1038/nrd4051 Many clinical trial failures can be traced back to the limited predictive value of preclinical models of disease. Plenge and colleagues discuss how knowledge from human genetics, such as naturally occurring mutations in humans that affect the activity of particular proteins, can be used as a tool to more effectively prioritize molecular targets in drug development. Abstract | Full Text | PDF
Novel therapies for hepatitis C — one pill fits all? Michael P. Manns & Thomas von Hahn p595 | doi:10.1038/nrd4050 It has been 25 years since the hepatitis C virus (HCV) was discovered. Now, pipelines are bristling with exciting new direct-acting antiviral drugs, many of which are in late-stage clinical trials. In this Review, Manns and von Hahn examine the future of anti-HCV therapy, the prospect of all-oral interferon-free treatment regimens, and discuss the key challenges faced by clinicians and drug developers. Abstract | Full Text | PDF
Therapeutic modulators of STAT signalling for human diseases Gabriella Miklossy, Tyvette S. Hilliard & James Turkson p611 | doi:10.1038/nrd4088 Members of the signal transducer and activator of transcription (STAT) protein family are implicated in a variety of diseases. In particular, aberrant activation of STAT3 is known to promote malignant transformation. In this Review, Turkson and colleagues discuss the various therapeutic approaches used to modulate the activation of the different STAT family members, which include dimerization inhibitors, tyrosine kinase inhibitors and DNA decoys. Abstract | Full Text | PDF
Emerging paradigms in GPCR allostery: implications for drug discovery Denise Wootten, Arthur Christopoulos & Patrick M. Sexton p630 | doi:10.1038/nrd4052 Allosteric ligands bind to G protein-coupled receptors at a site distinct from the endogenous ligand. This Review discusses the potential advantages that allosteric ligands could hold, and highlights how the complexity of their actions provides both challenges and opportunities for drug screening. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: The 'rule of three' for fragment-based drug discovery: where are we now? Harren Jhoti, Glyn Williams, David C. Rees & Christopher W. Murray p644 | doi:10.1038/nrd3926-c1 Full Text | PDF
Advertisement
Nature Outlook Leukaemia While survival rates for some types of leukaemia have improved dramatically, this family of blood cancers remains a potentially fatal disease. Research in epigenetics, immunotherapy, and cell transplants offers hope.  Access the Outlook free online for six months.  Produced with support from: Novartis Oncology, Baxter International, Onconova Therapeutics
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.